Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (7628)
All Articles published online
|
Publishing Process of This Article
|
May 28, 2015 (publication date) through Nov 8, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Schneitler S, Kröpil P, Riemer J, Antoch G, Knoefel WT, Häussinger D, Graf D. Metastasized pancreatic carcinoma with neoadjuvant FOLFIRINOX therapy and R0 resection. World J Gastroenterol 2015; 21(20): 6384-6390 [PMID: 26034375 DOI: 10.3748/wjg.v21.i20.6384] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v21/i20/6384.htm |
| Number | Citing Articles |
| 1 |
Junji Furuse, Junji Shibahara, Masanori Sugiyama. Development of chemotherapy and significance of conversion surgery after chemotherapy in unresectable pancreatic cancer. Journal of Hepato-Biliary-Pancreatic Sciences 2018; 25(5): 261 doi: 10.1002/jhbp.547
|
| 2 |
Yoonhyeong Byun, Youngmin Han, Jae Seung Kang, Yoo Jin Choi, Hongbeom Kim, Wooil Kwon, Sun‐Whe Kim, Do‐Youn Oh, Sang Hyub Lee, Ji Kon Ryu, Yong‐Tae Kim, Jin‐Young Jang. Role of surgical resection in the era of FOLFIRINOX for advanced pancreatic cancer. Journal of Hepato-Biliary-Pancreatic Sciences 2019; 26(9): 416 doi: 10.1002/jhbp.648
|
| 3 |
Dezső Kelemen, László Mangel, Zsolt Szabó, Ádám Varga, András Palkovics, András Vereczkei. Májáttétes pancreasrák: meghosszabbítható-e a túlélés az oligoperzisztens primer daganat neoadjuváns kemoterápiát követő reszekciójával?. Orvosi Hetilap 2023; 164(43): 1712 doi: 10.1556/650.2023.32900
|
| 4 |
L. T. Wang, J. Yang, J. Wu, W. J. Lu. Combined Therapy of Chemotherapy and Radiofrequency Ablation for Pancreatic Cancer Patients With Metachronous Hepatic Metastatic Lesions After Radical Pancreatic Resection. Cancer Control 2024; 31 doi: 10.1177/10732748241274559
|
| 5 |
Masanori Tsujie, Soichi Fumita, Tomoko Wakasa, Shigeto Mizuno, Hajime Ishikawa, Kotaro Kitani, Shumpei Satoi, Kaoru Okada, Keisuke Inoue, Shuichi Fukuda, Hironobu Manabe, Noriko Ichimura, Shinya Ueda, Takao Tamura, Toshihiko Kawasaki, Masao Yukawa, Yoshio Ohta, Masatoshi Inoue. A Case of Pathological Complete Response Following FOLFIRINOX Therapy for Pancreatic Adenocarcinoma with Synchronous Distant Lymph Node Metastases. International Journal of Surgery Case Reports 2020; 72: 471 doi: 10.1016/j.ijscr.2020.06.044
|
| 6 |
Valentina Fanotto, Francesca Salani, Caterina Vivaldi, Mario Scartozzi, Dario Ribero, Marco Puzzoni, Francesco Montagnani, Francesco Leone, Enrico Vasile, Maria Bencivenga, Giovanni De Manzoni, Debora Basile, Lorenzo Fornaro, Gianluca Masi, Giuseppe Aprile. Primary Tumor Resection for Metastatic Colorectal, Gastric and Pancreatic Cancer Patients: In Search of Scientific Evidence to Inform Clinical Practice. Cancers 2023; 15(3): 900 doi: 10.3390/cancers15030900
|
| 7 |
Wenjie Lu, Lantian Wang, Jianyao Lou, Kezhong Tang. Sequential therapy for pancreatic cancer patients with synchronous oligo-hepatic metastatic lesions. Tumori Journal 2023; 109(3): 307 doi: 10.1177/03008916221110265
|
| 8 |
Mingxing Wang, Pengfei Zhu, Zheling Chen, Liu Yang. Conversion therapy, palliative chemotherapy and surgery, which of these is the best treatment for locally advanced and advanced pancreatic cancer?. Anti-Cancer Drugs 2022; 33(1): e686 doi: 10.1097/CAD.0000000000001235
|
| 9 |
Ottavia De Simoni, Marco Scarpa, Marco Tonello, Pierluigi Pilati, Francesca Tolin, Ylenia Spolverato, Mario Gruppo. Oligometastatic Pancreatic Cancer to the Liver in the Era of Neoadjuvant Chemotherapy: Which Role for Conversion Surgery? A Systematic Review and Meta-Analysis. Cancers 2020; 12(11): 3402 doi: 10.3390/cancers12113402
|
| 10 |
Andreas Brandl, Christina Barbara Schäfer, Beate Rau. Unusual Cases in Peritoneal Surface Malignancies. 2017; : 71 doi: 10.1007/978-3-319-51523-6_6
|
| 11 |
Akashi FUJITA, Susumu HIJIOKA, Yasuhiro SHIMIZU, Yoshiki SENDA, Seiji NATSUME, Nobumasa MIZUNO, Nozomi OKUNO, Masahiro TAJIKA, Tsutomu TANAKA, Makoto ISHIHARA, Yutaka HIRAYAMA, Sachiyo OHNISHI, Takashi HIRAYAMA, Hitoshi SHIBUYA, Hisashi KONDO, Hirotaka SUZUKI, Kazuhiro TORIYAMA, Hiromichi IWAYA, Ayako ITO, Naosuke KURAOKA, Shinpei MATSUMOTO, Yasumasa NIWA, Kazuo HARA. Two patients with stage IVb pancreatic ductal adenocarcinoma who underwent margin-negative resection after long-term favorable response to gemcitabine monotherapy. Suizo 2017; 32(1): 78 doi: 10.2958/suizo.32.78
|
| 12 |
Clémence Breton, Antoine Meyer, David Malka, Margarida Matias, Thierry De Baere, Pascal Hammel, Antonio Sa Cunha, Angelica Lucchese, David Fuks, Romain Coriat, Claire Gallois, Yann Touchefeu, Marianne Maillet, Isabelle Trouilloud, Pierre Rompteaux, Franck Carbonnel, Emilie Soularue. Local treatment of pancreatic cancer metastases: A multicenter French study of the AGEO group. Clinics and Research in Hepatology and Gastroenterology 2021; 45(6): 101607 doi: 10.1016/j.clinre.2020.101607
|
| 13 |
G. Paul Wright, Katherine E. Poruk, Mazen S. Zenati, Jennifer Steve, Nathan Bahary, Melissa E. Hogg, Amer H. Zuriekat, Christopher L. Wolfgang, Herbert J. Zeh, Matthew J. Weiss. Primary Tumor Resection Following Favorable Response to Systemic Chemotherapy in Stage IV Pancreatic Adenocarcinoma with Synchronous Metastases: a Bi-institutional Analysis. Journal of Gastrointestinal Surgery 2016; 20(11): 1830 doi: 10.1007/s11605-016-3256-2
|
| 14 |
Si Shi, Xian-Jun Yu. Time to think: Selecting patients who may benefit from synchronous resection of primary pancreatic cancer and liver metastases. World Journal of Gastroenterology 2018; 24(33): 3677-3680 doi: 10.3748/wjg.v24.i33.3677
|
| 15 |
Hideyuki Yoshitomi, Shigetsugu Takano, Katsunori Furukawa, Tsukasa Takayashiki, Satoshi Kuboki, Masayuki Ohtsuka. Conversion surgery for initially unresectable pancreatic cancer: current status and unresolved issues. Surgery Today 2019; 49(11): 894 doi: 10.1007/s00595-019-01804-x
|
| 16 |
Zhongyan Zhang, Hongfeng Lin, Hehe Li, Xin Wang. A case report of surgical resection treatment for complete remission after chemotherapy for advanced pancreatic cancer. Frontiers in Oncology 2023; 13 doi: 10.3389/fonc.2023.1155233
|
| 17 |
S. A. Safi, N. Lehwald-Tywuschik, A. Rehders, G. Fluegen, L. Haeberle, V. Keitel, W. T. Knoefel. Site of relapse of ductal adenocarcinoma of the pancreas affects survival after multimodal therapy. BMC Surgery 2021; 21(1) doi: 10.1186/s12893-021-01082-w
|
| 18 |
Young Hoon Choi, Sang Hyub Lee, Min Su You, Bang Sup Shin, Woo Hyun Paik, Ji Kon Ryu, Yong-Tae Kim, Wooil Kwon, Jin-Young Jang, Sun-Whe Kim. Prognostic Factors for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer Receiving Neoadjuvant FOLFIRINOX. Gut and Liver 2021; 15(2): 315 doi: 10.5009/gnl19182
|
| 19 |
Jiachun Ding, Jiaqiang Ren, Fan Chen, Yangyang Yue, Chao Ren, Xirui Wang, Qingyong Ma, Zheng Wu, Zheng Wang. Prognostic Nomogram for pancreatic cancer with lung metastasis: a SEER database-based study. Journal of Pancreatology 2021; 4(1): 28 doi: 10.1097/JP9.0000000000000059
|
| 20 |
Katsuhito Teramatsu, Nao Fujimori, Masatoshi Murakami, Sho Yasumori, Kazuhide Matsumoto, Kohei Nakata, Masafumi Nakamura, Yutaka Koga, Yoshinao Oda, Yoshihiro Ogawa. Pathological complete response with FOLFIRINOX therapy for recurrence of pancreatic acinar cell carcinoma. Clinical Journal of Gastroenterology 2024; 17(4): 776 doi: 10.1007/s12328-024-01983-2
|
| 21 |
Toru Takematsu, Hiromitsu Hayashi, Takaaki Higashi, Takanobu Yamao, Norio Uemura, Kazuki Matsumura, Hideaki Takeyama, Kensuke Yamamura, Katsunori Imai, Yo-ichi Yamashita, Hideo Baba. Successful Treatment for the Recurrent Liver Metastases of the Pancreatic Cancer by Multimodality Therapy. Pancreas 2020; 49(8): e75 doi: 10.1097/MPA.0000000000001622
|
| 22 |
Joan Maurel, Santiago Sánchez-Cabús, Berta Laquente, Lydia Gaba, Laura Visa, Joan Fabregat, Ignacio Povés, Susana Roselló, Roberto Díaz-Beveridge, Marta Martín-Richard, Javier Rodriguez, Luis Sabater, Carles Conill, María Cambray, Ana Reig, Juan Ramón Ayuso, Carlos Valls, Antonio Ferrández, Josep Antoni Bombí, Angels Ginés, Xabier García-Albéniz, Laureano Fernández-Cruz. Outcomes after neoadjuvant treatment with gemcitabine and erlotinib followed by gemcitabine–erlotinib and radiotherapy for resectable pancreatic cancer (GEMCAD 10-03 trial). Cancer Chemotherapy and Pharmacology 2018; 82(6): 935 doi: 10.1007/s00280-018-3682-9
|
| 23 |
Andreas Minh Luu, Philipp Hoehn, Sina Rabea Vogel, Anke Reinacher-Schick, Johanna Munding, Waldemar Uhl, Chris Braumann. Pathologic Complete Response of Pancreatic Cancer following Neoadjuvant FOLFIRINOX Treatment in Hepatic Metastasized Pancreatic Cancer. Visceral Medicine 2019; 35(6): 387 doi: 10.1159/000497827
|
| 24 |
Paige T Shelemey, Carla P Amaro, Danny Ng, Vincent Falck, Vincent C Tam. Metastatic pancreatic cancer with complete response to FOLFIRINOX treatment. BMJ Case Reports 2021; 14(5): e238395 doi: 10.1136/bcr-2020-238395
|
| 25 |
C.-S. Leonhardt, T. Stamm, T. Hank, G. Prager, O. Strobel. Defining oligometastatic pancreatic cancer: a systematic review and critical synthesis of consensus. ESMO Open 2023; 8(6): 102067 doi: 10.1016/j.esmoop.2023.102067
|
| 26 |
Mitsuhiro Shimura, Masamichi Mizuma, Hiroki Hayashi, Akiko Mori, Tomoyoshi Tachibana, Tatsuo Hata, Masahiro Iseki, Tatsuyuki Takadate, Kyohei Ariake, Shimpei Maeda, Hideo Ohtsuka, Naoaki Sakata, Takanori Morikawa, Kei Nakagawa, Takeshi Naitoh, Takashi Kamei, Fuyuhiko Motoi, Michiaki Unno. A long-term survival case treated with conversion surgery following chemotherapy after diagnostic metastasectomy for pancreatic cancer with synchronous liver metastasis. Surgical Case Reports 2017; 3(1) doi: 10.1186/s40792-017-0409-9
|
| 27 |
Paul Georg Werthmann, Pia Inter, Thilo Welsch, Anne-Kathrin Sturm, Robert Grützmann, Markus Debus, Martin-Günther Sterner, Gunver Sophia Kienle. Long-term tumor-free survival in a metastatic pancreatic carcinoma patient with FOLFIRINOX/Mitomycin, high-dose, fever inducing Viscum album extracts and subsequent R0 resection. Medicine 2018; 97(49): e13243 doi: 10.1097/MD.0000000000013243
|
| 28 |
S. A. Safi, G. Fluegen, A. Rehders, L. Haeberle, S. Fung, V. Keitel, A. Krieg, W. T. Knoefel, N. Lehwald-Tywuschik. Surgical margin clearance and extended chemotherapy defines survival for synchronous oligometastatic liver lesions of the ductal adenocarcinoma of the pancreas. International Journal of Clinical Oncology 2021; 26(10): 1911 doi: 10.1007/s10147-021-01961-5
|
| 29 |
Sami-Alexander Safi, Lena Haeberle, Alexander Rehders, Stephen Fung, Sascha Vaghiri, Christoph Roderburg, Tom Luedde, Farid Ziayee, Irene Esposito, Georg Fluegen, Wolfram Trudo Knoefel. Neoadjuvant Treatment Lowers the Risk of Mesopancreatic Fat Infiltration and Local Recurrence in Patients with Pancreatic Cancer. Cancers 2021; 14(1): 68 doi: 10.3390/cancers14010068
|
| 30 |
Andreea Iliesiu, Radu-Valeriu Toma, Ana Ciongariu, Radu Costea, Narcis Zarnescu, Liviu Bîlteanu. A pancreatic adenocarcinoma mimicking hepatoid carcinoma of uncertain histogenesis: A case report and literature review. Oncology Letters 2023; 26(4) doi: 10.3892/ol.2023.14029
|
| 31 |
Chengfang Wang, Yingsheng Wu, Weilin Wang. Neoadjuvant therapy for resectable pancreatic cancer: a narrative review. Journal of Pancreatology 2022; 5(2): 69 doi: 10.1097/JP9.0000000000000091
|
| 32 |
Kenjiro Okada, Kenichiro Uemura, Wataru Okamoto, Tatsuaki Sumiyoshi, Ryuta Shintakuya, Hiroyuki Otsuka, Masahiro Serikawa, Yasutaka Ishii, Koji Arihiro, Shinya Takahashi. Pathologic complete response following FOLFIRINOX and olaparib treatment for hepatic metastasized pancreatic ductal adenocarcinoma with a germline BRCA mutation. Clinical Journal of Gastroenterology 2023; 16(2): 283 doi: 10.1007/s12328-022-01741-2
|
| 33 |
Kentaro Ozaki, Hiromitsu Hayashi, Yoshiaki Ikuta, Toshiro Masuda, Shinichi Akaboshi, Kenichi Ogata, Katsutaka Matumoto, Katsuhiro Ogawa, Takihiro Kamio, Hideo Baba, Hiroshi Takamori. Conversion surgery for initially unresectable pancreatic ductal adenocarcinoma with synchronous liver metastasis after treatment with FOLFIRINOX. Clinical Journal of Gastroenterology 2019; 12(6): 603 doi: 10.1007/s12328-019-00965-z
|
| 34 |
Yuta Kobayashi, Sakae Maeda, Naoki Hama, Atsushi Miyamoto, Mamoru Uemura, Masakazu Miyake, Kazuhiro Nishikawa, Motohiro Hirao, Takeshi Kato, Mitsugu Sekimoto, Kiyoshi Mori, Masayuki Mano, Shoji Nakamori. Successful conversion surgery for unresectable pancreatic cancer with peritoneal metastases after neoadjuvant albumin-bound paclitaxel and gemcitabine chemotherapy: case report and literature review. International Cancer Conference Journal 2018; 7(1): 20 doi: 10.1007/s13691-017-0311-0
|
| 35 |
Takatoshi SEKI, Takeshi FUJISHIRO, Taro MASHIKO, Yoshito MASUOKA, Misuzu YAMADA, Daisuke FURUKAWA, Naoki YAZAWA, Yohei KAWASHIMA, Masami OGAWA, Yoshiaki KAWAGUCHI, Tetuya MINE, Yousuke KUNISHI, Toshio NAKAGOHRI. Conversion therapy of FOLFIRINOX for pancreatic head cancer with liver metastasis: a case report. Suizo 2017; 32(6): 891 doi: 10.2958/suizo.32.891
|
| 36 |
Tianqiang Jin, Chaoliu Dai, Feng Xu. Surgical and local treatment of hepatic metastasis in pancreatic ductal adenocarcinoma: recent advances and future prospects. Therapeutic Advances in Medical Oncology 2020; 12 doi: 10.1177/1758835920933034
|
| 37 |
Duorui Nie, Guihua Lai, Guilin An, Zhuojun Wu, Shujun Lei, Jing Li, Jianxiong Cao. Individualized Prediction of Survival Benefits of Pancreatectomy Plus Chemotherapy in Patients With Simultaneous Metastatic Pancreatic Cancer. Frontiers in Oncology 2021; 11 doi: 10.3389/fonc.2021.719253
|
| 38 |
Thilo Hackert, Milena Sachsenmaier, Ulf Hinz, Lutz Schneider, Christoph W. Michalski, Christoph Springfeld, Oliver Strobel, Dirk Jäger, Alexis Ulrich, Markus W. Büchler. Locally Advanced Pancreatic Cancer. Annals of Surgery 2016; 264(3): 457 doi: 10.1097/SLA.0000000000001850
|